Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.48 |
| ▸ | ATF4 | P18848 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20381570 | 0.88 | ALDH1A1 (0.50) | ALDH1A1EPHX2ATF4THRBATM | |
| SCHEMBL16152211 | 0.81 | L3MBTL1 (0.62) | ALDH1A1THRBATML3MBTL1MEN1 | |
| SCHEMBL18330504 | 0.80 | EPHX2 (0.57) | EPHX2ATF4EPHX1 | |
| SCHEMBL18330456 | 0.78 | ALDH1A1 (0.56) | ALDH1A1ATML3MBTL1MEN1KMT2A | |
| SCHEMBL13451441 | 0.77 | EPHX2 (0.43) | EPHX2EPHX1KDM5AHSD11B1 | |
| SCHEMBL13451773 | 0.77 | EPHX2 (0.43) | EPHX2EPHX1KDM5AHSD11B1 | |
| SCHEMBL13627859 | 0.77 | EPHX2 (0.43) | ALDH1A1EPHX2EPHX1KDM5A | |
| SCHEMBL22875052 | 0.77 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1 | |
| SCHEMBL27877748 | 0.76 | EPHX2 (0.43) | ALDH1A1EPHX2EPHX1KDM5AMEN1 | |
| SCHEMBL19002252 | 0.76 | EPHX2 (0.60) | EPHX2THRBATML3MBTL1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | ALDH1A1 2644/4885EPHX2 4129/4885ATF4 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.